A new mutation has been found in the MECP2 gene — associated with most Rett syndrome cases — in…
Vanda Pinto, PhD
Vanda is a biochemist with a PhD in biomedicine from the University of Porto, Portugal. She conducted her postdoctoral research first at the Bristol Medical School, U.K., studying the insulin-PI3K/Akt signaling pathway in diabetic nephropathy, then at the Institute of Molecular Pathology and Immunology of the University of Porto, where her focus was on glycosylation in lupus nephritis and inflammatory bowel disease. She next made the switch to science publishing, handling papers in biochemistry, molecular biology, and immunology.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Vanda Pinto, PhD
Taysha Gene Therapies is partnering with Astellas Pharma to support the development of its gene therapy programs for…
The Rett Syndrome Research Trust (RSRT) has received a large donation from SANTÉ Realty Investments, a provider of…
The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease and orphan drug designations to DepYmed’s orally…
The International Rett Syndrome Foundation (IRSF) has seen its federal funding efforts rewarded in the U.S. as a bill…
A six-month intensive and individualized exercise program prevented the progression of scoliosis, a sideways curvature of the spine, in most girls…
Neurons activated at the same time — a state called neuronal synchrony — and with lesser complexity in the relationships…
Stem cells engineered to produce a constant level of a downstream target of the MECP2 protein, called brain-derived neurotrophic factor…
Treatment with fluoxetine, a type of antidepressant sold under the brand name Prozac, increased the number of cells producing…
Shape Therapeutics has raised $112 million in financing to support work into developing its portfolio of RNA technologies to…